SCHEMBL10248879

SCHEMBL10248879

Cc1ccc2c(c1)nc(-c1cc[n+]([O-])cc1)n2C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.49
CA2 P00918 2/20 0.49
CA12 O43570 1/20 0.49
CA9 Q16790 1/20 0.49
ACSS2 Q9NR19 1/20 0.45
NLRP3 Q96P20 1/20 0.44
KDM4E B2RXH2 4/20 0.43
HSD17B10 Q99714 4/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 5/20 0.41
NPC1 O15118 4/20 0.41
MAPT P10636 3/20 0.41
HPGD P15428 2/20 0.41
HTT P42858 2/20 0.41
GFER P55789 2/20 0.41
POLB P06746 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
RAB9A P51151 4/20 0.41
PKM P14618 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL167798 0.82 CA12 (0.44) CA1CA2CA12CA9KDM4E
SCHEMBL1104834 0.81 NLRP3 (0.65) CA1CA2CA12CA9ACSS2
SCHEMBL10249140 0.80 MEN1 (0.66) CA1CA2CA12CA9ACSS2
SCHEMBL10248962 0.79 AGPAT2 (0.41) CA1CA2CA12CA9ACSS2
SCHEMBL10030014 0.78 NLRP3 (0.61) CA1CA2CA12CA9ACSS2
SCHEMBL10252567 0.77 BRD4 (0.37) CA1CA2CA12CA9NLRP3
SCHEMBL30425393 0.77 CA1 (0.64) CA1CA2CA12CA9ACSS2
SCHEMBL17149164 0.76 HDAC1 (0.49) CA1CA2CA12CA9ACSS2
SCHEMBL15080534 0.76 CA12 (0.49) CA1CA2CA12CA9ACSS2
SCHEMBL14075988 0.76 ALDH1A1 (0.68) CA1CA2CA12CA9ACSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461181-B2 Fused heterocyclic compound and use thereof SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2013-06-11 US disclosed
US-8273764-B2 Fused heterocyclic compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-25 US disclosed
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-07-12 US disclosed
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 CA1 2069/4885CA2 3296/4885CA12 3308/4885
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 CA1 2069/4885CA2 3296/4885CA12 3308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.